Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124
Expand allThis document outlines details of PBS-subsidised daratumumab, elotuzumab, elranatamab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma (MM).
For details on how to process a PBS Authority, see:
- Processing Complex Authority Required Listings
- Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
- Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
On this page:
Multiple myeloma (MM) quick reference - Initial and Balance of Supply
Multiple myeloma (MM) quick reference - Continuing and no treatment phase
Newly diagnosed triple therapy (21-day cycle for 8 cycles)
Newly diagnosed triple therapy (28-day cycle for 6 cycles)
Multiple myeloma (MM) quick reference - Initial and Balance of Supply
Table 1
|
Restrictions |
Treatment type |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self- serve |
|
Initial Newly diagnosed PB291 form |
Monotherapy (lenalidomide) |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Newly diagnosed PB200 form |
Dual therapy (lenalidomide and dexamethasone) |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Newly diagnosed PB293 form |
Triple therapy (lenalidomide, bortezomib and dexamethasone) |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Newly diagnosed (week 0-24) |
Triple therapy (daratumumab, lenalidomide and dexamethasone) |
Telephone Electronic S85: daratumumab S100 EFC and CT: daratumumab |
No |
OPA |
Not specified |
Yes |
|
Grandfather Newly diagnosed |
Triple therapy (daratumumab, lenalidomide and dexamethasone) |
Telephone Electronic S85: daratumumab S100 EFC and CT: daratumumab |
No |
OPA |
Not specified |
Yes |
|
Balance of Supply Newly diagnosed (cycles 5-6 or cycles 5-8) |
Triple therapy (lenalidomide, bortezomib and dexamethasone) |
Telephone Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial |
Dual therapy (pomalidomide and dexamethasone) |
Written Electronic S100: pomalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Progressive disease PB158 form |
Monotherapy (lenalidomide) or dual therapy (lenalidomide and dexamethasone) |
Written Electronic S100: lenalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Progressive disease |
Triple therapy (pomalidomide, bortezomib and dexamethasone)) |
Telephone Electronic S100: pomalidomide |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma |
Monotherapy (elranatamab) |
Telephone Electronic S85 elranatamab S100 CT: elranatamab (general listing) |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma |
Dual therapy (selinexor and dexamethasone) |
Telephone Electronic S100: selinexor (general listing) |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma (week 1-9) |
Triple therapy (daratumumab, bortezomib and dexamethasone) |
Telephone Electronic S85: daratumumab S100 EFC and CT: daratumumab (general listing) |
No |
OPA |
Not specified |
Yes |
|
Initial Relapsed and/or refractory multiple myeloma |
Triple therapy (selinexor, bortezomib and dexamethasone) |
Telephone Electronic S100: selinexor (general listing) |
No |
OPA |
Not specified |
Yes |
Multiple myeloma (MM) quick reference - Continuing and no treatment phase
Table 2
Newly diagnosed triple therapy (21-day cycle for 8 cycles)
Table 3
|
Step |
Treatment phase |
Drug combination |
Treatment cycle |
Quantity and repeats |
Authority level |
|
1 |
Initial |
lenalidomide, dexamethasone and bortezomib |
Cycle 1 - 4 |
|
Written (PB293) Electronic |
|
2 |
Continuing triple |
lenalidomide, dexamethasone and bortezomib |
Cycle 5 - 8 (21-day) OR Cycle 5 - 6 (28-day) |
OR
|
Telephone Electronic |
|
3 |
Continuing dual therapy (if continued on 21-day cycle) OR if changed to 28-day cycle If ineligible for Stem Cell Transplant (SCT) Initial newly diagnosed dual therapy If post SCT Initial newly diagnosed monotherapy |
Continuing dual therapy lenalidomide and dexamethasone Ineligible for SCT lenalidomide and dexamethasone Post SCT lenalidomide |
Continuing dual therapy (21-day cycle) Cycle 9 and beyond Switching to 28-day cycle N/A |
Continuing dual therapy (21-day cycle)
Ineligible for SCT
Post SCT
|
Continuing dual therapy (21-day cycle) Telephone Electronic Ineligible for SCT Written (PB200) Electronic Post SCT Written (PB291) Electronic |
Newly diagnosed triple therapy (28-day cycle for 6 cycles)
Table 4
|
Step |
Treatment phase |
Drug combination |
Treatment cycle |
Quantity and repeats |
Authority level |
|
1 |
Initial |
lenalidomide, dexamethasone and bortezomib |
Cycle 1 - 4 |
|
Written (PB293) Electronic |
|
2 |
Continuing triple |
lenalidomide, dexamethasone and bortezomib |
Cycle 5 - 6 (28-day) OR Cycle 5 - 8 (21-day) |
OR
|
Telephone Electronic |
|
3 |
If continued on 28-day cycle If ineligible for SCT Initial newly diagnosed dual therapy If post SCT Initial newly diagnosed monotherapy OR Continuing dual therapy (if changed to 21-day cycle) |
Ineligible for SCT lenalidomide and dexamethasone Post SCT lenalidomide Continuing dual therapy lenalidomide and dexamethasone |
Continuing 28-day cycle N/A Continuing dual therapy (21-day cycle) Cycle 9 and beyond |
Ineligible for SCT
Post SCT
Continuing dual therapy
|
Ineligible for SCT Written (PB200) Electronic Post SCT Written (PB291) Electronic Continuing dual therapy (21-day cycle) Telephone Electronic |